Find industry news, trends, and innovative products right here in our blog.
A
B
C
D
E
G
H
I
J
L
M
N
O
P
R
S
T
U
V
W
X
Compare AOD-9604 vs Tesamorelin in fat-reduction research: direct adipocyte lipolysis, GHRH-driven GH release, IGF-1 signaling, and visceral fat data.
A research-focused comparison of Retatrutide vs Mazdutide, contrasting triple- and dual-receptor architecture, hepatic vs systemic endpoints, and current Phase 2/3 evidence.
Tirzepatide vs Retatrutide in obesity and metabolic research: how triple GLP-1/GIP/glucagon receptor agonism differs from dual incretin activation.
Compare CJC-1295 vs Tesamorelin as GHRH analogues in visceral fat and metabolic research, with phase III VAT data, IGF-1 kinetics, and protocol notes.
Cagrilintide vs semaglutide research: how amylin and GLP-1 pathways drive satiety, why they combine in CagriSema, and what REDEFINE 1 showed at 68 weeks.
CJC-1295 vs Sermorelin compared for GHRH research: half-life, GH pulsatility, IGF-1 exposure, and endpoint selection for laboratory study design.
Compare CJC-1295 vs Ipamorelin for GH research, including GHRH vs GHS-R1a signaling, pulsatile vs sustained release, and combination rationale.
Compare Aliaxin vs Restylane, two popular dermal fillers, by exploring their similarities, differences, and ideal applications.
Semaglutide vs Tirzepatide research: compare GLP-1 vs dual GLP-1/GIP receptor agonism, SURMOUNT and SUSTAIN outcomes, and protocol design considerations.
Compare Ipamorelin vs GHRP-6 in preclinical research: GHS-R1a selectivity, cortisol and appetite differences, and pulsatile GH pulse amplitude data.
Compare IGF-1 DES vs IGF-1 LR3 for anabolic signaling research: IGFBP binding, half-life around 20–30 hours, and choosing local vs systemic variants for in vitro or in vivo...
Research into Selank is an active field within peptide science, primarily focused on its potential as a non-sedative anxiolytic and cognitive enhancer.
Subscribe for exclusive offers and updates on new arrivals